Best rated global clinical trial supply companies by ClientPharma

Quality clinical research commercial drug supply from ClientPharma: We work closely with you to provide market insights needed in order to implement the best strategy to meet your commercial drug supply requirements. Our client testimonials attest to our unique, collaborative approach, which adds longstanding value and strong partnerships. Our aim is to understand your goals and to work to minimize waste, allowing you to reinvest those savings back into your R&D initiatives. We hold ourselves to the highest standards, delivering on time, and most importantly, with uncompromised quality and integrity. Discover more details on clinical research commercial drug supply.

True commitment to patient safety: ClientPharma is also committed to proactively driving quality — not only because it’s the foundation from which the pharmaceutical industry has been built, but we also understand the significance of the patients’ safety and well-being. It’s our professional duty to service our clients’ needs with the utmost attention and care. CP also has a personal stake in supporting the development of future medicines that will treat and help eliminate life threatening diseases, ensuring we enhance our lives and those of our loved ones.

Experts in accessing biosimilars and reference medicines that others cannot. We pride ourselves on the ability to access commercial medicines that others cannot, especially from challenging markets while always providing premier service and excellent, consultative guidance throughout your project. We overcome your comparator sourcing challenges. ClientPharma’s clinical trial project management team brings proficiency in overseeing and overcoming your commercial drug supply challenges.

On May 20th, we celebrate International Clinical Trials Day 2023. It is a day to reflect on the ground-breaking work and significant contributions of clinical trials in advancing medical research, improving patient care and transforming lives worldwide. Our heartfelt gratitude goes out to the patients participating in clinical trials and we extend our appreciation to all those that make the clinical trials possible; the researchers, physicians, nurses, and healthcare professionals, with their unwavering dedication to bring new and innovative treatments to those in need. Together we can shape the future of medicine and make a lasting impact on the lives of millions. Happy International Clinical Trials Day! Find more information at clientpharma.com.

Andrea Chopek, President, North America at ClientPharma relayed, “Our industry is yearning for a sleek, global approach for commercial drug supply — and with this strategic partnership, we offer that. Together, we solve drug supply difficulties and navigate the many complexities — reducing supply chain risks and managing waste and costs throughout the stages of your clinical trial. Two industry leaders coming together doesn’t dilute the solution, it provides one concentrated, easy solution for our clients.” Jeff Wiltrout, Ph.D., Senior Vice President of Business Development at TrialCard, stated, “The responsibilities of clinical trial supply and operations personnel are vast and intricate. They need partners that make complex tasks simple and efficient. The partnership between market leaders like TrialCard and ClientPharma simplifies our clients’ global commercial drug sourcing responsibilities by providing a variety of streamlined, agile and efficient processes.”

Supply and demand of pharmaceuticals are mutually exclusive. The supply chain is wholly reliant upon pharmaceutical companies being able to effectively forecast demand for a particular product. The process of forecasting is often made difficult when a new medicine has just been brought to market or rapid deployment of a drug needs to happen in response to a pandemic due to a lack of concrete evidence to base estimations on. In a survey of pharmaceutical Senior Managers it was reported that the majority of pharmaceutical companies had miscalculated demand for new medicines by up to 25%. Michael Lehmann, executive vice president of sales and marketing for Patheon, a global provider of outsourced pharmaceutical development and manufacturing said, “Making accurate demand forecasts is extremely challenging for pharmaceutical companies”.